Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMA NYSE:OGEN NASDAQ:RDHL NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$6.45+3.5%$0.81$5.74▼$37.90$3.97M0.56189,143 shs97,087 shsOGENOragenics$1.25-0.8%$2.85$1.23▼$75.60$1.03M0.95347,719 shs108,700 shsRDHLRedhill Biopharma$1.20-8.4%$1.90$1.18▼$19.15$3.01M4.221.41 million shs166,123 shsSNGXSoligenix$2.74-6.5%$1.59$1.09▼$5.40$9.56M1.8719.02 million shs7.78 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics+934.98%+822.48%+867.02%+641.46%+275.00%OGENOragenics-0.79%-10.07%-13.19%-78.62%-95.99%RDHLRedhill Biopharma-8.40%-29.82%-40.00%-42.03%-99.50%SNGXSoligenix-6.48%+107.58%+117.46%+43.76%-34.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRMADermata Therapeutics0.4806 of 5 stars1.53.00.00.00.60.80.0OGENOragenics0.2087 of 5 stars0.04.00.00.00.60.00.0RDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASNGXSoligenix2.0373 of 5 stars3.52.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 3.00Buy$3.00-53.49% DownsideOGENOragenics 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/ASNGXSoligenix 3.00Buy$6.00118.98% UpsideCurrent Analyst Ratings BreakdownLatest OGEN, SNGX, DRMA, and RDHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$0.62 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/ARDHLRedhill Biopharma$8.04M0.34N/AN/A($3.66) per share-0.33SNGXSoligenix-$117.03K-76.42N/AN/A$1.64 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-270.81%-179.96%8/6/2025 (Estimated)OGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/ARDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ASNGXSoligenix-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)Latest OGEN, SNGX, DRMA, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025SNGXSoligenix-$0.79N/AN/AN/AN/AN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/9/2025Q1 2025SNGXSoligenix-$0.67-$1.06-$0.39-$1.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A3.703.70OGENOragenicsN/A1.931.93RDHLRedhill BiopharmaN/A0.540.37SNGXSoligenixN/A1.851.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%OGENOragenics18.71%RDHLRedhill Biopharma7.20%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics18.50%OGENOragenics4.90%RDHLRedhill Biopharma6.81%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics86.38 million5.20 millionNot OptionableOGENOragenics5823,00010.98 millionN/ARDHLRedhill Biopharma2102.30 million2.14 millionNo DataSNGXSoligenix203.26 million3.16 millionNot OptionableOGEN, SNGX, DRMA, and RDHL HeadlinesRecent News About These CompaniesPromising Small Cap Stocks To Consider - July 31stAugust 2 at 4:49 AM | americanbankingnews.comSoligenix has phase IIa success in rare disease Behçet'sAugust 1 at 8:10 AM | bioworld.comBWhy Is Soligenix Stock (SNGX) Up 50% Today?August 1 at 3:09 AM | msn.comSoligenix (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s DiseaseJuly 31 at 5:07 PM | theglobeandmail.comSNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…July 31 at 5:07 PM | finance.yahoo.comBiological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's DiseaseJuly 31 at 7:30 AM | prnewswire.comTargeting the Unmet: Soligenix (NASDAQ: SNGX) Building Portfolio for Rare ConditionsJuly 28, 2025 | theglobeandmail.comSNGX: Multiple Catalysts Upcoming in 2H25…July 11, 2025 | finance.yahoo.comSoligenix Corporate Update Letter - Key Highlights and Upcoming MilestonesJuly 8, 2025 | prnewswire.comSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - Seeking AlphaJuly 3, 2025 | seekingalpha.comSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma SolutionsJuly 1, 2025 | prnewswire.comSoligenix Approves 2025 Equity Incentive Plan at MeetingJune 20, 2025 | tipranks.comSoligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s DiseaseJune 17, 2025 | theglobeandmail.comSoligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | finance.yahoo.comSoligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | globenewswire.comSoligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer TrialMay 24, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial ResultsMay 20, 2025 | theglobeandmail.comSNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…May 13, 2025 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug Power3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsNew Catalyst Sends Joby Stock to 52-Week HighsBy Jeffrey Neal Johnson | July 15, 2025View New Catalyst Sends Joby Stock to 52-Week HighsOGEN, SNGX, DRMA, and RDHL Company DescriptionsDermata Therapeutics NASDAQ:DRMA$6.45 +0.22 (+3.50%) Closing price 08/1/2025 03:55 PM EasternExtended Trading$6.54 +0.09 (+1.40%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Oragenics NYSE:OGEN$1.25 -0.01 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Redhill Biopharma NASDAQ:RDHL$1.20 -0.11 (-8.40%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.23 +0.03 (+2.58%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Soligenix NASDAQ:SNGX$2.74 -0.19 (-6.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.77 +0.03 (+1.09%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
